16 DEcember 2011 – Parsortix update

The group’s 90% owned company, Parsortix, has achieved another important milestone with the news that its cell separation device can capture cultured lung cancer cells.  The technology has already established that it can capture both breast cancer and prostrate cancer cells.  This is more excellent news for the company and we continue to rate the shares as a BUY.